Raine Garrido

Raine Garrido

Auto-generated profile, based on publicly available information

Raine Garrido

Finlay Institute of Vaccines, Ave 27 Nr. 19805, Havana, Cuba

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
YMYanira Méndez
Yanira Méndez
JCJanoi Chang
Janoi Chang
AHAna R. Humpierre
Ana R. Humpierre
AZAbel Zanuy
Abel Zanuy
RGRaine Garrido
Raine Garrido
DRDaniel G. Rivera
Daniel G. Rivera
A new synthetic strategy for the development of multivalent antibacterial glycoconjugate vaccines is described. The approach comprises the utilization of an isocyanide-based multicomponent process for the conjugation of functionalized capsular polysaccharides of S. pneumoniae and S. Typhi to carrier proteins such as diphtheria and tetanus toxoids. For the first time, oxo- and carboxylic acid-functionalized polysaccharides could be either independently or simultaneously conjugated to immunogenic proteins by means of the Ugi-multicomponent reaction, thus leading to mono- or multivalent unimolecular glycoconjugates as vaccine candidates. Despite the high molecular weight of the two or three reacting biomolecules, the multicomponent bioconjugation proved highly efficient and reproducible. The Ugi-derived glycoconjugates showed notable antigenicity and elicited good titers of functional specific antibodies. To our knowledge, this is the only bioconjugation method that enables the incorporation of two different polysaccharidic antigens to a carrier protein in a single step. Applications in the field of self-adjuvanting, eventually anticancer, multicomponent vaccines are foreseeable.

8 December 2021 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
DSDarielys Santana-Mederos
Darielys Santana-Mederos
RPRocmira Pérez-Nicado
Rocmira Pérez-Nicado
YCYanet Climent
Yanet Climent
LRLaura Rodriguez
Laura Rodriguez
BRBelinda Sanchez Ramirez
Belinda Sanchez Ramirez
VBVicente Verez Bencomo
Vicente Verez Bencomo
Soberana01 is composed of the SARS-CoV-2 dimeric RBD and Neisseria meningitidis outer membrane vesicles (OMVs) adsorbed on alum. This vaccine induces a potent neutralizing immune response and shows potential against SARS-CoV-2 variants of concern.

1 November 2012 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RGRaine Garrido
Raine Garrido
APAlain Puyada
Alain Puyada
AFAnaís Fernández
Anaís Fernández
MGMajela González
Majela González
URUbel Ramírez
Ubel Ramírez
HVHermán Vélez
Hermán Vélez

1 November 2012 in Vaccine
Verified
Journal Article
Closed access
JCJanoi Chang
Janoi Chang
YSYohanna Serrano
Yohanna Serrano
RGRaine Garrido
Raine Garrido
LRLaura M. Rodríguez
Laura M. Rodríguez
JPJessy Pedroso
Jessy Pedroso
VVVicente Verez-Bencomo
Vicente Verez-Bencomo

1 January 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
RGRaine Garrido
Raine Garrido
BBBárbara Baró
Bárbara Baró
JSJean Pierre Soubal
Jean Pierre Soubal
DSDarielys Santana
Darielys Santana

11 March 2022 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
AHAna R. Humpierre
Ana R. Humpierre
AZAbel Zanuy
Abel Zanuy
MSMirelys Saenz
Mirelys Saenz
AVAldrin Vasco Vidal
Aldrin Vasco Vidal
YMYanira Méndez
Yanira Méndez
RGRaine Garrido
Raine Garrido